Cubist Systematic Strategies LLC Increases Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Cubist Systematic Strategies LLC increased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 26.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,166 shares of the company’s stock after buying an additional 4,415 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Syndax Pharmaceuticals were worth $363,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its stake in Syndax Pharmaceuticals by 380.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,400 shares of the company’s stock valued at $41,000 after purchasing an additional 1,900 shares during the last quarter. Royal Bank of Canada grew its stake in Syndax Pharmaceuticals by 833.6% during the 1st quarter. Royal Bank of Canada now owns 2,530 shares of the company’s stock valued at $57,000 after purchasing an additional 2,259 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in Syndax Pharmaceuticals by 48.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,525 shares of the company’s stock valued at $61,000 after purchasing an additional 1,145 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Syndax Pharmaceuticals by 36.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,473 shares of the company’s stock valued at $111,000 after purchasing an additional 1,729 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in Syndax Pharmaceuticals by 8.6% during the 2nd quarter. Arizona State Retirement System now owns 10,247 shares of the company’s stock valued at $176,000 after purchasing an additional 812 shares during the last quarter.

In other Syndax Pharmaceuticals news, COO Michael A. Metzger sold 4,808 shares of the stock in a transaction that occurred on Tuesday, September 21st. The stock was sold at an average price of $19.16, for a total transaction of $92,121.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Fabrice Egros sold 14,030 shares of the stock in a transaction that occurred on Thursday, November 18th. The shares were sold at an average price of $18.03, for a total value of $252,960.90. The disclosure for this sale can be found here. Insiders sold a total of 158,291 shares of company stock valued at $3,088,194 in the last ninety days. 7.60% of the stock is currently owned by insiders.

SNDX has been the topic of several research analyst reports. Zacks Investment Research downgraded Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 20th. Morgan Stanley boosted their price target on Syndax Pharmaceuticals from $20.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, October 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $27.89.

Shares of SNDX opened at $16.83 on Thursday. Syndax Pharmaceuticals, Inc. has a 52 week low of $13.02 and a 52 week high of $27.85. The company has a quick ratio of 10.81, a current ratio of 10.81 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $831.27 million, a price-to-earnings ratio of -8.95 and a beta of 1.41. The stock’s 50-day moving average price is $18.46 and its 200-day moving average price is $17.52.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, November 15th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.24. Syndax Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 6,031.18%. During the same period in the prior year, the business earned ($0.46) EPS. As a group, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Featured Article: What are high-yield dividend stocks?

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.